trending Market Intelligence /marketintelligence/en/news-insights/trending/RaVUV7jARaYWZ-m34SKYpg2 content esgSubNav
In This List

Becton Dickinson, Bard deal gets conditional nod from EU regulator

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Becton Dickinson, Bard deal gets conditional nod from EU regulator

The European Commission granted conditional approval to Becton Dickinson and Co.'s $24 billion acquisition of C. R. Bard Inc.

As part of the clearance, Becton Dickinson must divest its core needle biopsy devices business and tissue marker product line.

Closing of the deal is expected to occur in the fourth calendar quarter of 2017, subject to customary closing conditions and additional regulatory approvals, including the U.S. Federal Trade Commission and other regulatory bodies.